Clinical Trial Update: Central Pain Study for ABX-1431 [Phase 1]

View source ↗

Summary

Phase 1 central pain study of ABX-1431 conducted by Abide Therapeutics has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Longitudinally Extensive Transverse Myelitis
• Multiple Sclerosis
• Neuromyelitis Optica Spectrum Disorder
• Transverse Myelitis

Drugs mentioned

• ABX-1431 (ABX-1431)

Snippet

Sponsor: Abide Therapeutics | Conditions: Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis | Phase 1 | Status: COMPLETED